Viewing Study NCT04624204


Ignite Creation Date: 2025-12-24 @ 8:00 PM
Ignite Modification Date: 2025-12-27 @ 6:06 AM
Study NCT ID: NCT04624204
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-02
First Post: 2020-11-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module